Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$1.4B
143M shares
52-week range
$7.71 – $15.48
29% from low
Sector
SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC
Exchange
NYSE
CS
Borrow rate
0.41%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2016 | 2017 | 2018 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.11B | $3.00B | $4.16B | $4.87B | $5.13B | $5.41B | $5.97B | $6.32B |
| Cost of revenue | $0 | $0 | $0 | $927.3M | $955.2M | $140.8M | $1.03B | $155.7M |
| Gross profit | $2.11B | $3.00B | $4.16B | $3.94B | $4.17B | $5.27B | $4.93B | $6.17B |
| Gross margin | 100.0% | 100.0% | 100.0% | 81.0% | 81.4% | 97.4% | 82.7% | 97.5% |
| R&D | $0 | $19.9M | $15.7M | $0 | $0 | $0 | $0 | $0 |
| Operating income | $84.8M | $121.8M | $149.8M | $436.6M | $217.0M | $229.5M | $405.8M | $325.6M |
| EBITDA | $142.8M | $230.9M | $245.8M | $526.9M | $531.7M | $350.0M | $574.9M | $497.3M |
| Net income | $14.6M | −$35.6M | −$143.0M | $154.3M | $188.9M | $50.3M | $210.3M | $135.8M |
| Net margin | 0.7% | -1.2% | -3.4% | 3.2% | 3.7% | 0.9% | 3.5% | 2.1% |
| EPS (diluted) | 0.10 | -0.25 | -1.01 | 1.08 | 1.32 | 0.35 | 1.58 | 0.96 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $6.5B | $1.12 | $1.08–$1.19 | 5 |
| 2027 | $6.8B | $1.28 | $1.17–$1.36 | 6 |
| 2028 | $7.2B | $1.36 | $1.07–$1.63 | 6 |
Forward consensus · source: Financial Modeling Prep
Ardent Health Inc is a provider of healthcare in growing mid-sized urban communities across the U.S and operating in eight growing mid-sized urban markets across six states Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas. The main focus on people and investments in services and technologies.
www.ardenthealth.comNo one on the platform currently holds ARDT.
| Institution | Shares | Reported |
|---|---|---|
| Third Point LLCas of 2025-06-30 | 75,000 | $1.0M |
| Renaissance Technologiesas of 2025-09-30 | 10,700 | $141.8K |
No one on the platform has traded ARDT yet.
| $1.9B |
| — |
| BKDBrookdale Senior Living Inc. | $15.86 | +0.95% | $3.8B | — |
| IBRXImmunityBio, Inc. | $8.77 | +0.69% | $9.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ARDT i really like the way this company earns and i think handling health care in the manner they do is optimal. I'm going to restart a position in a few hours
View on StockTwits ↗$ARDT Healthcare providers and medical device manufacturers report strong Q1 2026 earnings driven by product approvals, expanded commercial investments, and accelerating procedure volumes with margin expansion from operational efficiency. Learn more: https://axlfi.com/themes/220
View on StockTwits ↗$ARDT Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.28 down -6.67% YoY • Reported revenue of $1.6B up 6.99% YoY • Ardent Health is reaffirming its full-year 2026 guidance, expecting total revenue between $6.4B and $6.7B, and Adjusted EBITDA between $485M and $535M.
View on StockTwits ↗$ARDT Financial Performance Summary The Company's first quarter 2026 results included a $10.9 million gain, included in other operating expenses, from an increase in the carrying value of an investment option it holds in a privately held company. For the first quarter of 2026: Total revenue grew 7.0% year-over-year to $1,602 million, driven primarily by a 2.0% increase in adjusted admissions and a 5.5% increase in net patient service revenue per adjusted admission. Net income attributable to Ardent Health was $40 million, or $0.28 per diluted share, compared to net income attributable to Ardent Health of $41 million, or $0.29 per diluted share, in the first quarter of 2025. Adjusted EBITDA increased 26.3% year-over-year to $124 million. Excluding the $10.9 million gain discussed above, adjusted EBITDA grew 15%.
View on StockTwits ↗$ARDT https://ir.ardenthealth.com/financials/quarterly-results/default.aspx
View on StockTwits ↗$ARDT Share Price: $9.34 Contract Selected: Jan 15, 2027 $10 Calls Buy Zone: $1.61 – $1.98 Target Zone: $2.76 – $3.37 Potential Upside: 62% ROI Time to Expiration: 281 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$ARDT Q4 '25 Earnings Results & Recap Ardent Health is issuing full-year 2026 guidance, expecting total revenue between $6.4B and $6.7B, and Adjusted EBITDA between $485M and $535M.
View on StockTwits ↗$ARDT is a clinical-stage biotech developing therapies for cancer and inflammatory diseases; its pipeline is early-stage, representing a high-risk investment.
View on StockTwits ↗$ARDT Current Stock Price: $9.33 Contracts to trade: $10 ARDT Jan 16 2026 Call Entry: $0.18 Exit: $0.29 ROI: 60% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$ARDT new 5 day low with ugly daily candle. Switching to bearish. Looking for a bounce down to around 8.
View on StockTwits ↗$ARDT could be a hidden gym with only 78 watchers. A P/E of about 6.2 and forward P/E is at about 6.9 is extremely low for a hospital operator. Revenue is around 6.33b and that’s a substantial footprint for a midcap healthcare operator. They have solid probability of a net income of $205M (ttm).
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.